Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Randomized, Blinded, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics, With an Open-Label Target Occupancy Study of BIIB113 in Healthy Participants

NCT05195008 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT05195008
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05195008 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Randomized, Blinded, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics, With an Open-Label Target Occupancy Study of BIIB113 in Healthy Participants
Lead sponsor
Biogen
Phase
Phase 1
Overall status
Completed
Start date
January 24, 2022
Completion date
July 10, 2023
Enrollment
72 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteer